Literature DB >> 1371720

Allogeneic tumor-specific cytotoxic T lymphocytes.

J M Redd1, A C Lagarde, C A Kruse, D Bellgrau.   

Abstract

We report the development of cytotoxic T lymphocytes specific for an allogeneic brain tumor in a rat model. DA strain cytotoxic T cell precursors stimulated by an allogeneic tumor (9L gliosarcoma) from the Fischer rat could generate a population of cytotoxic T lymphocytes that lysed the allogeneic 9L tumor but failed to lyse other targets, including Fischer concanavalin-A(ConA)-stimulated lymphoid blast targets. DA T cells depleted of reactivity to the Fischer haplotype (DA-F) retained reactivity to the 9L tumor, demonstrating that T cell precursors with specificity for normal Fischer alloantigens were not required for the generation of a response to the 9L Fischer tumor. The preferential lysis of the tumor target did not simply reflect a higher density of Fischer target antigens on the tumor than that found on normal Fischer ConA blast targets. First, the relative densities of class I antigen on the 9L tumor and normal Fischer ConA blasts were comparable. Second, cytotoxic T cells could not be generated from DA-F precursors when Fischer ConA blasts were used as stimulators. If DA-F T cells were simply responding to the higher density of Fischer antigen found on 9L tumor, it would have been expected that the ConA blasts expressing comparable levels of antigen to that found on the tumor would have generated cytotoxicity for both the 9L and ConA targets. We conclude that the cytotoxic T cells are specific for a determinant expressed only by the tumor. Such tumor-specific cytotoxic T cells could be useful in vivo for adoptive immunotherapy of brain tumors.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1371720     DOI: 10.1007/bf01741557

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  33 in total

1.  T cells mediate transplantation tolerance.

Authors:  S Dorsch; B Roser
Journal:  Nature       Date:  1975-11-20       Impact factor: 49.962

2.  The expression of a tissue-specific self-peptide is required for allo-recognition.

Authors:  I J Molina; B T Huber
Journal:  J Immunol       Date:  1990-03-15       Impact factor: 5.422

3.  Cytotoxic T-cell precursors with low-level CD8 in the diabetes-prone Biobreeding rat: implications for generation of an autoimmune T-cell repertoire.

Authors:  D Bellgrau; A C Lagarde
Journal:  Proc Natl Acad Sci U S A       Date:  1990-01       Impact factor: 11.205

4.  SPECIFIC positive and negative selection of rat lymphocytes reactive to strong histocompatibility antigens: activation with alloantigens in vitro and in vivo.

Authors:  D B Wilson; A Marshak; J C Howard
Journal:  J Immunol       Date:  1976-04       Impact factor: 5.422

5.  Immunotherapy for recurrent malignant glioma: an interim report on survival.

Authors:  M Ingram; J G Buckwalter; D B Jacques; D B Freshwater; R M Abts; G B Techy; K Miyagi; C H Shelden; R W Rand; L W English
Journal:  Neurol Res       Date:  1990-12       Impact factor: 2.448

6.  In vitro studies on the cell-mediated immune response to human brain tumors. I. Requirement for third-party stimulator lymphocytes in the induction of cell-mediated cytotoxic responses to allogeneic cultured gliomas.

Authors:  M K Gately; M Glaser; S J Dick; R W Mettetal; P L Kornblith
Journal:  J Natl Cancer Inst       Date:  1982-12       Impact factor: 13.506

7.  Imbalances in T cell subpopulations in human gliomas.

Authors:  M K Bhondeley; R D Mehra; N K Mehra; A K Mohapatra; P N Tandon; S Roy; V Bijlani
Journal:  J Neurosurg       Date:  1988-04       Impact factor: 5.115

8.  Interleukin-2-activated lymphocytes from brain tumor patients. A comparison of two preparations generated in vitro.

Authors:  C A Kruse; D H Mitchell; K O Lillehei; S D Johnson; E L McCleary; G E Moore; S Waldrop; G W Mierau
Journal:  Cancer       Date:  1989-10-15       Impact factor: 6.860

9.  Histocompatibility antigen-activated cytotoxic T lymphocytes. II. Estimates of the frequency and specificity of precursors.

Authors:  K F Lindahl; D B Wilson
Journal:  J Exp Med       Date:  1977-03-01       Impact factor: 14.307

10.  The generation of killer cells to trinitrophenyl-modified allogeneic targets by lymphocyte populations negatively selected to strong alloantigens.

Authors:  D B Wilson; K F Lindahl; D H Wilson; J Sprent
Journal:  J Exp Med       Date:  1977-08-01       Impact factor: 14.307

View more
  8 in total

1.  Ex vivo expansion of tumor-draining lymph node cells using compounds which activate intracellular signal transduction. II. Cytokine production and in vivo efficacy of glioma-sensitized lymphocytes.

Authors:  C D Rice; N G Baldwin; R T Biron; H D Bear; R E Merchant
Journal:  J Neurooncol       Date:  1997-03       Impact factor: 4.130

2.  Implementing preclinical study findings to protocol design: translational studies with alloreactive CTL for gliomas.

Authors:  Michelle J Hickey; Colin C Malone; Kate E Erickson; German G Gomez; Emma L Young; Linda M Liau; Robert M Prins; Carol A Kruse
Journal:  Am J Transl Res       Date:  2012-01-10       Impact factor: 4.060

Review 3.  Immunologic approaches to therapy for brain tumors.

Authors:  D B Paul; C A Kruse
Journal:  Curr Neurol Neurosci Rep       Date:  2001-05       Impact factor: 5.081

4.  Intracranial administrations of single or multiple source allogeneic cytotoxic T lymphocytes: chronic therapy for primary brain tumors.

Authors:  C A Kruse; P M Schiltz; D Bellgrau; Q Kong; B K Kleinschmidt-DeMasters
Journal:  J Neurooncol       Date:  1994       Impact factor: 4.130

5.  Interactions of the allogeneic effector leukemic T cell line, TALL-104, with human malignant brain tumors.

Authors:  German G Gomez; Susana B Read; Lazaro E Gerschenson; Daniela Santoli; Adam Zweifach; Carol A Kruse
Journal:  Neuro Oncol       Date:  2004-04       Impact factor: 12.300

6.  A rat glioma model, CNS-1, with invasive characteristics similar to those of human gliomas: a comparison to 9L gliosarcoma.

Authors:  C A Kruse; M C Molleston; E P Parks; P M Schiltz; B K Kleinschmidt-DeMasters; W F Hickey
Journal:  J Neurooncol       Date:  1994       Impact factor: 4.130

7.  Immunoresistant human glioma cell clones selected with alloreactive cytotoxic T lymphocytes: downregulation of multiple proapoptotic factors.

Authors:  German G Gomez; Michelle J Hickey; Richard Tritz; Carol A Kruse
Journal:  Gene Ther Mol Biol       Date:  2008-06

8.  Gamma interferon transduced 9L gliosarcoma. Cytokine gene therapy and its relevance to cellular therapy with alloreactive cytotoxic T lymphocytes.

Authors:  David B Paul; Susana B Read; Nisha V Kulprathipanja; German G Gomez; B K Kleinschmidt-DeMasters; Patric M Schiltz; Carol A Kruse
Journal:  J Neurooncol       Date:  2003 Aug-Sep       Impact factor: 4.130

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.